What are the recommended acyclovir dosing regimens for varicella and herpes zoster in immunocompetent adults, children (2 months to 12 years), and immunocompromised patients?

Acyclovir Dosing for Varicella and Herpes Zoster

Herpes Zoster (Shingles)

For herpes zoster in immunocompetent adults and children, administer acyclovir 800 mg orally five times daily for 7-10 days, initiated within 72 hours of rash onset. 1

Key Dosing Details:

• Timing is critical: Treatment must begin within 72 hours of rash onset for maximum efficacy 2
• Optimal window: Starting within 48 hours provides the greatest benefit, particularly for adults over 50 years 1
• Duration: 7 days is typically sufficient, though 10 days may be used 1

Clinical Benefits:

When initiated early, acyclovir significantly:

• Accelerates cutaneous healing and time to lesion scabbing
• Reduces duration of viral shedding
• Decreases acute pain severity and duration
• Reduces formation of new lesions
• May decrease prevalence of localized zoster-associated neurologic symptoms (paresthesia, dysesthesia, hyperesthesia) 1, 3

Immunocompromised Patients:

For immunocompromised patients with herpes zoster, use intravenous acyclovir 500 mg/m² (or 10 mg/kg) every 8 hours for 7 days. 4, 5

This regimen is essential because it:

• Prevents progression of cutaneous dissemination
• Halts visceral complications
• Reduces acute pain more effectively than oral therapy in this high-risk population 4

---

Varicella (Chickenpox)

Children (2 months to 12 years):

For otherwise healthy children with varicella, administer acyclovir 20 mg/kg orally four times daily (maximum 800 mg per dose) for 5 days, initiated within 24 hours of rash onset. 1

• Children over 40 kg: Use adult dose of 800 mg four times daily 1
• Critical timing: Must start within 24 hours of rash appearance 1

Important caveat: The 2007 ACIP guidelines note that routine acyclovir use in healthy children is not recommended because the clinical benefit is modest—it reduces fever duration and lesion count but does not significantly reduce complications or school absence 2. However, when treatment is indicated, the above dosing applies.

When to Consider Treatment in Otherwise Healthy Patients:

Oral acyclovir should be considered for:

• Persons aged >12 years (adolescents and adults have more severe disease)
• Persons with chronic cutaneous or pulmonary disorders
• Persons receiving long-term salicylate therapy
• Persons receiving short, intermittent, or aerosolized corticosteroids
• Secondary household contacts (who typically develop more severe disease) 2

Adults and Adolescents (>12 years):

For immunocompetent adults and adolescents with varicella, use acyclovir 800 mg orally four times daily for 5 days, started within 24 hours of rash onset. 1

Clinical trials demonstrate that acyclovir is well-tolerated and effective in reducing duration and severity when given early 2.

Immunocompromised Patients:

For immunocompromised children and adults with varicella, use intravenous acyclovir 500 mg/m² every 8 hours for 7 days. 4, 5

This is the standard of care because:

• IV acyclovir significantly reduces varicella-associated morbidity and mortality
• Prevents visceral complications (most serious complication)
• Reduces pulmonary involvement
• Must be initiated within 24 hours of rash onset 2, 4

---

Renal Dose Adjustments

Critical: Acyclovir requires dose modification in renal impairment 1:

Normal Dose	Creatinine Clearance	Adjusted Dose
800 mg every 4 hours	>25 mL/min	800 mg every 4 hours
800 mg every 4 hours	10-25 mL/min	800 mg every 8 hours
800 mg every 4 hours	0-10 mL/min	800 mg every 12 hours

Hemodialysis patients: Administer an additional dose after each dialysis session 1

---

Common Pitfalls to Avoid

1. Missing the treatment window: Acyclovir loses efficacy if not started within 24 hours for varicella or 72 hours for zoster
2. Inadequate hydration: High-dose acyclovir (800 mg five times daily) requires adequate hydration to prevent crystalluria and renal complications 5
3. Forgetting renal adjustment: Failure to adjust for renal function can lead to neurotoxicity
4. Underdosing in VZV infections: VZV is less sensitive to acyclovir than HSV, requiring higher doses (800 mg vs 200-400 mg for HSV) 5

---

Pregnancy Considerations

Acyclovir is FDA Category B. While routine use is not recommended in pregnant women with uncomplicated varicella, intravenous acyclovir should be considered for serious viral-mediated complications such as pneumonia 2. A registry of 596 first-trimester exposures showed birth defect rates similar to the general population 2.